// App-Quantinova.ai

1329 : Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis

Researchers

Presenter

  • Mark Genovese

Principal Investigators

  • Bernard Combe

  • Yoshiya Tanaka

  • Alan Kivitz

  • Franziska Matzkies

  • Beatrix Bartok

  • Lei Ye

  • Ying Guo

  • Chantal Tasset

  • John Sundy

  • Edward Keystone

  • Rene Westhovens

  • William F.C. Rigby

  • Gerd Burmester

Medical Centers

  • Oregon Health and Science University, Portland, OR

  • CHU Montpellier, Montpellier University, Montpellier, France

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Altoona Center for Clinical Research, Duncansville, PA

  • Gilead Sciences, Inc., Foster City, CA

  • Galapagos, Mechelen, Belgium

  • Toronto General Hospital, University of Toronto, Toronto, ON, Canada

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Dartmouth College, Lebanon, NH

  • Charite-University Medicine Berlin, Berlin, Germany

Locations

  • United States

  • France

  • Japan

  • Belgium

  • Canada

  • Germany

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02889796

  • NCT02873936

  • NCT02886728

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved